No benefit to newer oral anticoagulants after ACS

In this systematic review of patients post-ACS on anti platelet therapy, the use of newer oral anticoagulants (rivaroxaban, apixaban, dabigatran) was associated with much higher risk of bleeding (odd ratio 3, CI 2.2 to 4.2), a moderate reduction in stent thrombosis/ischemia, and no overall change in mortality, compared to placebo. The overall net benefit of these agents was no different than placebo. The new oral anticoagulants do not appear to benefit patients post-ACS (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment